Naheed Ismaili Misfeldt, Venture Partner

Joined in 2003; 12 years experience in venture capital and corporate finance
Involved in the formation of specialty pharma, anti-infective, and molecular diagnostics companies at Aberdare and, earlier, Bay City Capital
Advised on healthcare M&A in addition to completing biotech IPOs while at Chase H&Q
Conducted research on genetics of diabetes and obesity at Rockefeller University
Kauffman Fellows Program; MPH, Columbia; BA Molecular/Cell Biology, UC Berkeley

Current Aberdare Boards:

HemaQuest Pharmaceuticals

Select Former Boards / Investments:

Clovis Oncology, Pharmion, Mpex Pharmaceuticals, Kai Pharmaceuticals

"With Naheed, it's all about the science. She reads and understands the background materials, asks thoughtful questions, and is always available to test out ideas and provide insightful advice. When Naheed speaks, we listen!" - Steven J. Mento, Ph.D., President and CEO, Conatus Pharmaceuticals Inc.

"Naheed is a valuable member of our board, she is extremely pleasant to interact with, keenly insightful and frequently the one who asks the hard questions that keep the board focused on the really significant issues facing the company." - John P Longenecker, CEO, HemaQuest Pharmaceuticals